LogicBio Therapeutics, Inc.

NasdaqGM:LOGC 株式レポート

時価総額:US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

LogicBio Therapeutics 配当金

配当金 基準チェック /06

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り1.9%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
一株当たり利益-US$0.81
配当利回り予想n/a

最近の配当金アップデート

更新なし

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

LogicBio EPS misses by $0.06, beats on revenue

May 10

LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo

Apr 27

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

LogicBio extends collaboration with Children's Medical Research Institute

Jan 07

LogicBio Therapeutics names new CFO

Dec 22

Looking In On LogicBio

Nov 17

LogicBio reports Q3 results

Nov 09

決済の安定と成長

配当データの取得

安定した配当: Insufficient data to determine if LOGC's dividends per share have been stable in the past.

増加する配当: Insufficient data to determine if LOGC's dividend payments have been increasing.


配当利回り対市場

LogicBio Therapeutics 配当利回り対市場
LOGC 配当利回りは市場と比べてどうか?
セグメント配当利回り
会社 (LOGC)n/a
市場下位25% (US)1.4%
市場トップ25% (US)4.3%
業界平均 (Biotechs)1.9%
アナリスト予想 (LOGC) (最長3年)n/a

注目すべき配当: Unable to evaluate LOGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

高配当: Unable to evaluate LOGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


株主への利益配当

収益カバレッジ: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


株主配当金

キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as LOGC has not reported any payouts.


高配当企業の発掘